Fibroblast growth factor 21: From pharmacology to physiology

American Journal of Clinical Nutrition

Volumn 91, Issue 1, 2010, Pages

  Kliewer, Steven A ^a,b   Mangelsdorf, David J ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 21; GLITAZONE DERIVATIVE; GROWTH HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHENTERMINE; PIOGLITAZONE; ROSIGLITAZONE; SOMATOMEDIN C; TRIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR; GLUCAGON; GROWTH PROMOTOR; INSULIN;

BODY GROWTH; CONFERENCE PAPER; DIET RESTRICTION; DRUG MECHANISM; GLUCONEOGENESIS; GROWTH INHIBITION; INSULIN SENSITIVITY; KETOGENESIS; LIPID METABOLISM; LIPID PEROXIDATION; METABOLIC REGULATION; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; DIABETES MELLITUS; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; HUMAN; LIVER; METABOLISM; MOUSE; PANCREAS; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIMATE; REVIEW; RODENT; STARVATION;

MUS; PRIMATES; RODENTIA;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; FIBROBLAST GROWTH FACTORS; GLUCAGON; GROWTH SUBSTANCES; HUMANS; INSULIN; LIVER; MICE; OBESITY; PANCREAS; PRIMATES; RODENTIA; STARVATION; TRIGLYCERIDES; WEIGHT LOSS;

EID: 74049108945     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.3945/ajcn.2009.28449B     Document Type: Conference Paper

References (40)

1. Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 2008;237:18-27.
2. Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007;27:3417-28.
3. Fukumoto S. Actions and mode of actions of FGF19 subfamily members. Endocr J 2008;55:23-31.
4. Kurosu H, Kuro OM. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 2009;299:72-8.
5. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000;1492:203-6.
6. Muise ES, Azzolina B, Kuo DW, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol 2008;74:403-12.
7. Kharitonenkov A, Dunbar JD, Bina HA, et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 2008;215:1-7.
8. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of beta-Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007;282:26687-95.
9. Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008;22:1006-14.
10. Ogawa Y, Kurosu H, Yamamoto M, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 2007;104:7432-7.
11. Ito S, Kinoshita S, Shiraishi N, et al. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev 2000;98:115-9.
12. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627-35.
13. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008;149:6018-27.
14. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009;58:250-9.
15. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007;148:774-81.
16. Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006;55:2470-8.
17. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007;5:426-37.
18. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007;5:415-25.
19. Lundasen T, Hunt MC, Nilsson LM, et al. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 2007;360:437-40.
20. Potthoff MJ, Inagaki T, Satapati S, et al. FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 2009;106:10853-8.
21. Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008;8:169-74.
22. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003;24:78-90.
23. Rhee J, Inoue Y, Yoon JC, et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci USA 2003;100:4012-7.
24. Yoon JC, Puigserver P, Chen G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001;413:131-8.
25. Burgess SC, Leone TC, Wende AR, et al. Diminished hepatic gluconeogenesis via defects in tricarboxylic acid cycle flux in peroxisome proliferator- activated receptor gamma coactivator-1alpha (PGC-1alpha)-deficient mice. J Biol Chem 2006;281:19000-8.
26. Andrews MT, Squire TL, Bowen CM, Rollins MB. Low-temperature carbon utilization is regulated by novel gene activity in the heart of a hibernating mammal. Proc Natl Acad Sci USA 1998;95:8392-7.
27. Zhang J, Kaasik K, Blackburn MR, Lee CC. Constant darkness is a circadian metabolic signal in mammals. Nature 2006;439:340-3.
28. Thissen JP, Underwood LE, Ketelslegers JM. Regulation of insulin-like growth factor-I in starvation and injury. Nutr Rev 1999;57:167-76.
29. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 2008;8:77-83.
30. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Ryden M. FGF21 attenuates lipolysis in human adipocytes: a possible link to improved insulin sensitivity. FEBS Lett 2008;582:1725-30.
31. Wang H, Qiang L, Farmer SR. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol 2008;28:188-200.
32. Chen WW, Li L, Yang GY, et al. Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008;116:65-8.
33. Li H, Bao Y, Xu A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and γ-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009;94:2151-6.
34. Li L, Yang G, Ning H, Yang M, Liu H, Chen W. Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Res Clin Pract 2008;82:209-13.
35. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57:1246-53.
36. Dostalova I, Kavalkova P, Haluzikova D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008;93:3627-32.
37. Blackburn GL. From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor γ modulators. Am J Clin Nutr 2010;91 (suppl):251S-3S.
38. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010;91(suppl):258S-61S.
39. Cheatham WW. Peroxisome proliferator-activated receptor translational research and clinical experience. Am J Clin Nutr 2010;91(suppl):262S-6S.
40. Higgins LS, DePaoli AM. Selective peroxisome proliferator-activated receptor γ (PPARγ) modulation as a strategy for safer therapeutic PPARγ activation. Am J Clin Nutr 2010;91(suppl):267S-72S.